NEWS
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
Repare Therapeutics announced positive initial data from their Phase 1 MINOTAUR trial, evaluating lunresertib in combination with FOLFIRI for advanced solid tumors.
The trial showed an overall response rate of 18.2% in heavily pretreated patients and a 51.5% clinical benefit rate. Among colorectal cancer (CRC) patients, 40% of irinotecan-naïve patients received treatment for over nine months.
The recommended Phase 2 dose (RP2D) was established at 60mg BID lunresertib continuous plus standard FOLFIRI. Importantly, the safety profile was consistent with FOLFIRI alone, with the most common serious adverse events being neutropenia and leukopenia.
These findings, presented at the ESMO GI Cancers Congress, suggest lunresertib combined with FOLFIRI could offer a new treatment option for patients with CCNE1 amplification and FBXW7 mutations, which lack approved therapies.
Repare Therapeutics announced positive initial data from their Phase 1 MINOTAUR trial, evaluating lunresertib in combination with FOLFIRI for advanced solid tumors.
The trial showed an overall response rate of 18.2% in heavily pretreated patients and a 51.5% clinical benefit rate. Among colorectal cancer (CRC) patients, 40% of irinotecan-naïve patients received treatment for over nine months.
The recommended Phase 2 dose (RP2D) was established at 60mg BID lunresertib continuous plus standard FOLFIRI. Importantly, the safety profile was consistent with FOLFIRI alone, with the most common serious adverse events being neutropenia and leukopenia.
These findings, presented at the ESMO GI Cancers Congress, suggest lunresertib combined with FOLFIRI could offer a new treatment option for patients with CCNE1 amplification and FBXW7 mutations, which lack approved therapies.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2311Followers
105Following
24KVisitors
Follow